These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19491335)

  • 41. Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa.
    Frackiewicz EJ; Jhee SS; Shiovitz TM; Webster J; Topham C; Dockens RC; Whigan D; Salazar DE; Cutler NR
    Ann Pharmacother; 2002 Feb; 36(2):225-30. PubMed ID: 11847938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder.
    Ibrahim L; Diaz Granados N; Jolkovsky L; Brutsche N; Luckenbaugh DA; Herring WJ; Potter WZ; Zarate CA
    J Clin Psychopharmacol; 2012 Aug; 32(4):551-7. PubMed ID: 22722512
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease.
    Kulisevsky J; Barbanoj M; Gironell A; Antonijoan R; Casas M; Pascual-Sedano B
    Clin Neuropharmacol; 2002; 25(1):25-31. PubMed ID: 11852293
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial.
    Yoritaka A; Takanashi M; Hirayama M; Nakahara T; Ohta S; Hattori N
    Mov Disord; 2013 Jun; 28(6):836-9. PubMed ID: 23400965
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.
    Ahlskog JE; Muenter MD; Bailey PA; Miller PM
    Clin Neuropharmacol; 1991 Jun; 14(3):214-27. PubMed ID: 1676932
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations.
    Clarke CE; Cooper JA; Holdich TA;
    Clin Neuropharmacol; 2001; 24(3):133-8. PubMed ID: 11391123
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.
    Stocchi F; Rascol O; Hauser RA; Huyck S; Tzontcheva A; Capece R; Ho TW; Sklar P; Lines C; Michelson D; Hewitt DJ;
    Neurology; 2017 Jun; 88(23):2198-2206. PubMed ID: 28490648
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM; Rascol A
    J Neurol Neurosurg Psychiatry; 1992 Jul; 55(7):630-1. PubMed ID: 1386383
    [No Abstract]   [Full Text] [Related]  

  • 49. NMDA antagonists as Parkinson's disease therapy: disseminating the evidence.
    Majláth Z; Vécsei L
    Neurodegener Dis Manag; 2014; 4(1):23-30. PubMed ID: 24640976
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia.
    Tsai CH; Huang HC; Liu BL; Li CI; Lu MK; Chen X; Tsai MC; Yang YW; Lane HY
    Psychiatry Clin Neurosci; 2014 Sep; 68(9):692-700. PubMed ID: 24612097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.
    Marrinan SL; Otiker T; Vasist LS; Gibson RA; Sarai BK; Barton ME; Richards DB; Hellström PM; Nyholm D; Dukes GE; Burn DJ
    Mov Disord; 2018 Feb; 33(2):329-332. PubMed ID: 29278279
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease.
    Michel A; Downey P; Nicolas JM; Scheller D
    PLoS One; 2014; 9(12):e114086. PubMed ID: 25513815
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A pilot study on the motor effects of rimantadine in Parkinson's disease.
    Evidente VG; Adler CH; Caviness JN; Gwinn-Hardy K
    Clin Neuropharmacol; 1999; 22(1):30-2. PubMed ID: 10047931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Supervised versus unsupervised technology-based levodopa monitoring in Parkinson's disease: an intrasubject comparison.
    Lopane G; Mellone S; Corzani M; Chiari L; Cortelli P; Calandra-Buonaura G; Contin M
    J Neurol; 2018 Jun; 265(6):1343-1352. PubMed ID: 29600390
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjuvant treatment of Parksinson's disease with budipine: a double-blind trial versus placebo.
    Jellinger K; Bliesath H
    J Neurol; 1987 Jun; 234(5):280-2. PubMed ID: 3302121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tremorlytic activity of budipine in Parkinson's disease.
    Spieker S; Eisebitt R; Breit S; Przuntek H; Müller D; Klockgether T; Dichgans J
    Clin Neuropharmacol; 1999; 22(2):115-9. PubMed ID: 10202609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New drugs for Parkinson's disease.
    Simonson W
    Geriatr Nurs; 2017; 38(3):244-245. PubMed ID: 28552205
    [No Abstract]   [Full Text] [Related]  

  • 58. Tremorlytic activity of budipine in Parkinson's disease.
    Spieker S; Breit S; Klockgether T; Dichgans J
    J Neural Transm Suppl; 1999; 56():165-72. PubMed ID: 10370910
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Little Change in Functional Brain Networks Following Acute Levodopa in Drug-Naïve Parkinson's Disease.
    White RL; Campbell MC; Yang D; Shannon W; Snyder AZ; Perlmutter JS
    Mov Disord; 2020 Mar; 35(3):499-503. PubMed ID: 31854465
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.
    Vanle B; Olcott W; Jimenez J; Bashmi L; Danovitch I; IsHak WW
    Transl Psychiatry; 2018 Jun; 8(1):117. PubMed ID: 29907742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.